|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
EP1535995A1
(en)
*
|
1998-12-31 |
2005-06-01 |
Chiron Corporation |
Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
|
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
JP2003523721A
(ja)
|
1998-12-31 |
2003-08-12 |
カイロン コーポレイション |
抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
|
|
GB9906177D0
(en)
|
1999-03-17 |
1999-05-12 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
DE50015096D1
(de)
*
|
1999-11-16 |
2008-05-21 |
Geneart Ag |
Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
|
|
AU2001245793A1
(en)
*
|
2000-03-16 |
2001-09-24 |
Cold Spring Harbor Laboratory |
Methods and compositions for rna interference
|
|
US8202846B2
(en)
*
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
GB0009760D0
(en)
*
|
2000-04-19 |
2000-06-07 |
Oxford Biomedica Ltd |
Method
|
|
ATE414794T1
(de)
*
|
2000-09-01 |
2008-12-15 |
Gen Probe Inc |
Amplifizierung von hiv-1 sequenzen zur detektion von sequenzen, die mit wirkstoff-resistenz mutationen einhergehen
|
|
WO2002022080A2
(en)
*
|
2000-09-15 |
2002-03-21 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
|
|
WO2002024897A2
(en)
*
|
2000-09-22 |
2002-03-28 |
Virxsys |
Conditionally replicating viral vectors and their use
|
|
GB0024550D0
(enExample)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
IL157087A0
(en)
|
2001-01-25 |
2004-02-08 |
Virxsys Corp |
A method for identifying a function of a gene sequence
|
|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US6835568B2
(en)
|
2001-10-30 |
2004-12-28 |
Virxsys Corporation |
Regulated nucleic acid expression system
|
|
ES2411981T3
(es)
*
|
2002-02-01 |
2013-07-09 |
Oxford Biomedica (Uk) Limited |
Vector lentivírico
|
|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
CA2723320C
(en)
|
2007-05-04 |
2019-06-11 |
University Health Network |
Il-12 immunotherapy for cancer
|
|
US20090088625A1
(en)
*
|
2007-10-01 |
2009-04-02 |
Kenneth Oosting |
Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery
|
|
US9169491B2
(en)
|
2008-06-18 |
2015-10-27 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
WO2012075337A2
(en)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
WO2014093965A1
(en)
*
|
2012-12-14 |
2014-06-19 |
Case Western Reserve University |
Genomic rna packaging enhancer element
|
|
DK2986635T3
(en)
|
2013-04-18 |
2019-01-28 |
Fond Telethon |
EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
|
|
GB201318804D0
(en)
|
2013-10-24 |
2013-12-11 |
Adaptimmune Ltd |
Vectors for transgene expression
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
SG11201701309SA
(en)
|
2014-09-15 |
2017-04-27 |
Molmed Spa |
Chimeric antigen receptors
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
CA3254091A1
(en)
*
|
2014-12-16 |
2025-10-27 |
C3J Therapeutics, Inc. |
Compositions of and methods for in vitro viral genome engineering
|
|
GB201519086D0
(en)
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
PL3380620T3
(pl)
|
2015-11-23 |
2024-11-12 |
Novartis Ag |
Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
|
|
GB201604146D0
(en)
|
2016-03-10 |
2016-04-27 |
Nightstarx Ltd |
Prenylation assay
|
|
EP3318285A1
(en)
|
2016-11-08 |
2018-05-09 |
Oxford University Innovation Limited |
Treatment of eye disease
|
|
EP3548618A1
(en)
|
2016-12-01 |
2019-10-09 |
Nestec S.A. |
Methods of modulating fam46a
|
|
EP3375876A1
(en)
|
2017-03-13 |
2018-09-19 |
Evonetix Ltd |
Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
|
|
JP2020515551A
(ja)
|
2017-03-31 |
2020-05-28 |
ソシエテ・デ・プロデュイ・ネスレ・エス・アー |
Ank1を調節する方法
|
|
SI3612624T1
(sl)
|
2017-04-21 |
2025-03-31 |
Ospedale San Raffaele S.R.L. |
Genska terapija
|
|
BR112019022321A2
(pt)
|
2017-04-24 |
2020-05-26 |
Ospedale San Raffaele S.R.L. |
Tcr e peptídeos
|
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
|
SG11202003462SA
(en)
|
2017-10-17 |
2020-05-28 |
Nightstarx Ltd |
Prenylation assay
|
|
EP3713580A1
(en)
|
2017-11-21 |
2020-09-30 |
Société des Produits Nestlé S.A. |
Methods of modulating alk
|
|
EP3502260A1
(en)
|
2017-12-22 |
2019-06-26 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
WO2019134866A1
(en)
|
2018-01-03 |
2019-07-11 |
Molmed Spa |
Chimeric antigen receptors containing optimal spacer region
|
|
IL278016B2
(en)
|
2018-04-18 |
2025-03-01 |
Ucl Business Ltd |
Method for Enhancing the Suppressive Properties of Treg Cells
|
|
BR112020023015A2
(pt)
|
2018-05-15 |
2021-02-17 |
Flagship Pioneering Innovations V, Inc. |
composições de fusossoma e usos das mesmas
|
|
WO2019219308A1
(en)
|
2018-05-17 |
2019-11-21 |
Societe Des Produits Nestle S.A. |
Methods of modulating nkx6.3
|
|
WO2019229109A1
(en)
|
2018-05-30 |
2019-12-05 |
Glycostem Therapeutics B.V. |
Car nk cells
|
|
EP3820509A1
(en)
|
2018-07-09 |
2021-05-19 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
GB201814203D0
(en)
|
2018-08-31 |
2018-10-17 |
King S College London |
Engineered regulatory t cell
|
|
GB201817821D0
(en)
|
2018-10-31 |
2018-12-19 |
Ospedale San Raffaele Srl |
TCR and peptides
|
|
JP2022507453A
(ja)
|
2018-11-14 |
2022-01-18 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
T細胞送達のためのフソソーム組成物
|
|
CA3120082A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
AU2019380517A1
(en)
|
2018-11-14 |
2021-06-03 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
EP3898947A1
(en)
|
2018-12-19 |
2021-10-27 |
King's College London |
Immunotherapeutic methods and compositions
|
|
GB201900687D0
(en)
|
2019-01-17 |
2019-03-06 |
King S College London |
Immunotherapeutic methods and compositions
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
KR20220034719A
(ko)
|
2019-03-10 |
2022-03-18 |
시오 진 테라피스 인코포레이티드 |
파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
GB201907493D0
(en)
|
2019-05-28 |
2019-07-10 |
Ospedale San Raffaele |
Agents and methods for treating viral infections
|
|
GB201912515D0
(en)
|
2019-08-30 |
2019-10-16 |
King S College London |
Engineered regulatory T cell
|
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
KR20220097492A
(ko)
|
2019-11-12 |
2022-07-07 |
옥스포드 바이오메디카(유케이) 리미티드 |
생산 시스템
|
|
KR20220139911A
(ko)
|
2020-02-13 |
2022-10-17 |
옥스포드 바이오메디카(유케이) 리미티드 |
렌티바이러스 벡터의 생산
|
|
GB2609103A
(en)
|
2020-02-25 |
2023-01-25 |
Quell Therapeutics Ltd |
Chimeric receptors for use in engineered cells
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
DE102020106710A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
EP4118217A1
(en)
|
2020-03-13 |
2023-01-18 |
Oxford BioMedica (UK) Limited |
Lentiviral vectors
|
|
CN116096866A
(zh)
|
2020-03-31 |
2023-05-09 |
萨那生物科技公司 |
靶向脂质颗粒及其组合物和用途
|
|
WO2021222222A1
(en)
|
2020-04-27 |
2021-11-04 |
Mccray Jr Paul B |
Compositions and methods for the treatment of cystic fibrosis
|
|
GB202007169D0
(en)
|
2020-05-14 |
2020-07-01 |
Ospedale San Raffaele Srl |
Epidermal growth factor receptor
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
GB202018657D0
(en)
|
2020-11-26 |
2021-01-13 |
Ospedale San Raffaele Srl |
Agents and methods for increasing liver immune response
|
|
US20240052015A1
(en)
|
2020-12-23 |
2024-02-15 |
Quell Therapeutics Limited |
Inducible signalling protein
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
JP2024506751A
(ja)
|
2021-02-01 |
2024-02-14 |
イプシレン バイオ エス.アール.エル. |
遺伝子サイレンシング
|
|
US20240101623A1
(en)
|
2021-02-15 |
2024-03-28 |
Ospedale San Raffaele S.R.L. |
Epigenetic silencing for treatment of cancer
|
|
GB202102637D0
(en)
|
2021-02-24 |
2021-04-07 |
Quell Therapeutics Ltd |
Engineered regulatory t cell
|
|
IL308356A
(en)
|
2021-05-12 |
2024-01-01 |
Fond Telethon |
Vector system
|
|
US20240254168A1
(en)
|
2021-05-28 |
2024-08-01 |
Sana Biotechnology, Inc. |
LIPID PARTICLES CONTAINING A TRUNCATED BABOON ENDOGENOUS RETROVIRUS (BaEV) ENVELOPE GLYCOPROTEIN AND RELATED METHODS AND USES
|
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
WO2023047100A1
(en)
|
2021-09-21 |
2023-03-30 |
Quell Therapeutics Ltd |
Anti-trem2 chimeric antigen receptor
|
|
TW202321286A
(zh)
|
2021-09-21 |
2023-06-01 |
英商圭爾醫療有限公司 |
抗p75ntr嵌合抗原受體
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
US20250000966A1
(en)
*
|
2021-10-13 |
2025-01-02 |
The Cleveland Clinic Foundation |
Mrna vaccine design via the alteration of codon usage
|
|
US20250230511A1
(en)
|
2021-10-29 |
2025-07-17 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
|
GB202117298D0
(en)
|
2021-11-30 |
2022-01-12 |
Quell Therapeutics Ltd |
Signalling protein
|
|
US20250059560A1
(en)
|
2021-12-16 |
2025-02-20 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4453022A1
(en)
|
2021-12-22 |
2024-10-30 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4209511A1
(en)
|
2022-01-05 |
2023-07-12 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies amd chimeric antigen receptors
|
|
US20250064853A1
(en)
|
2022-01-05 |
2025-02-27 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies and chimeric antigen receptors
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4269426A1
(en)
|
2022-04-29 |
2023-11-01 |
Ospedale San Raffaele S.r.l. |
Gene therapy
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
CA3261363A1
(en)
|
2022-07-08 |
2024-01-11 |
Ospedale San Raffaele S.R.L. |
TRANSGENIC CASSETTES
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024033544A1
(en)
|
2022-08-12 |
2024-02-15 |
Ospedale San Raffaele S.R.L. |
Deglycosylation of native glycoproteins expressed on a tumor cell surface
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
EP4615492A1
(en)
|
2022-11-08 |
2025-09-17 |
Ospedale San Raffaele S.r.l. |
Polynucleotide and vector
|
|
WO2024100294A1
(en)
|
2022-11-11 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Cdh17 car
|
|
GB202217541D0
(en)
|
2022-11-24 |
2023-01-11 |
Quell Therapeutics Ltd |
Recombinant receptor
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024133472A1
(en)
|
2022-12-22 |
2024-06-27 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4651887A1
(en)
|
2023-01-16 |
2025-11-26 |
Ospedale San Raffaele S.r.l. |
T-cell receptors
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
TW202436337A
(zh)
|
2023-01-23 |
2024-09-16 |
漢諾威醫學院 |
嵌合抗原受體
|
|
WO2024165859A1
(en)
|
2023-02-07 |
2024-08-15 |
Quell Therapeutics Limited |
Culture method for treg cells
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024194223A2
(en)
|
2023-03-17 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
WO2024194605A1
(en)
|
2023-03-17 |
2024-09-26 |
Quell Therapeutics Limited |
Treg therapy
|
|
WO2024194355A1
(en)
|
2023-03-20 |
2024-09-26 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024194642A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t regulatory cell
|
|
WO2024194649A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t cells and uses thereof
|
|
AU2024241563A1
(en)
|
2023-03-22 |
2025-10-09 |
Consiglio Nazionale Delle Ricerche |
Gene therapy
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
GB202307366D0
(en)
|
2023-05-17 |
2023-06-28 |
Ospedale San Raffaele Srl |
Vector
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024259299A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Compositions and methods for identification of vhh antibodies that bind a target antigen
|
|
WO2024261480A1
(en)
|
2023-06-21 |
2024-12-26 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
WO2025003481A2
(en)
|
2023-06-28 |
2025-01-02 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
WO2025032194A1
(en)
|
2023-08-08 |
2025-02-13 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
IT202300022191A1
(it)
|
2023-10-24 |
2025-04-24 |
Fond Telethon Ets |
Mezzi e metodi per la modifica genetica di uba1
|
|
WO2025109189A1
(en)
|
2023-11-24 |
2025-05-30 |
Ospedale San Raffaele S.R.L. |
Engineered regulatory t cells and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
EP4640830A1
(en)
|
2024-04-23 |
2025-10-29 |
Fondazione Telethon ETS |
Means and methods for safe and efficient gene editing in cells
|